1029126-16-6

Basic information

• Product Name: 6-bromo-5-oxo-hexanoic acid benzyl ester
• Synonyms: 6-bromo-5-oxo-hexanoic acid benzyl ester
• CAS NO: 1029126-16-6
• Molecular Weight: 299.164
• Mol File: 1029126-16-6.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 6-bromo-5-oxo-hexanoic acid benzyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 6-bromo-5-oxo-hexanoic acid benzyl ester(1029126-16-6)
• EPA Substance Registry System: 6-bromo-5-oxo-hexanoic acid benzyl ester(1029126-16-6)

Safety Data

• Hazardous Substances Data: 1029126-16-6(Hazardous Substances Data)

Upstream product

• 186581-53-3 diazomethane 
• 67852-85-1 glutaric acid chloride monobenzyl ester 
• 100-51-6 benzyl alcohol 
• 54322-10-0 glutaric acid monobenzyl ester 
• 68017-21-0 5-oxohexenoic acid benzyl ester 
• 108-55-4 glutaric anhydride, 

Downstream Products

• 1309767-12-1 tert-butyl 4-(3-((benzyloxy)carbonyl)propyl)-2-((di-tert-butoxycarbonyl)amino)-imidazole-1-carboxylate 
• 1029126-05-3 2-amino-4-(3-benzyloxycarbonyl-propyl)-imidazole-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Analogue synthesis reveals decoupling of antibiofilm and β-lactam potentiation activities of a lead 2-aminoimidazole adjuvant against Mycobacterium smegmatis

Biofilm formation is one of the many mechanisms bacteria utilize to survive antibiotic treatment. It has been demonstrated that when Mycobacterium tuberculosis exists in a biofilm in vitro, it expresses phenotypic resistance to antimicrobial drugs. As the in vivo survival of M.?tuberculosis following drug treatment is potentially linked to a biofilm-like expression of drug tolerance, it is hypothesized that biofilm dispersion should increase antibiotic susceptibility and reduce the duration of the current antibiotic treatment regimen. Previously, we have identified a 2-aminoimidazole (2-AI) compound capable of dispersing and inhibiting M.?tuberculosis and M.?smegmatis biofilms in vitro. Additionally, this compound potentiated the activity of carbenicillin against M.?tuberculosis and, to a lesser degree, M.?smegmatis. Here, we describe a SAR study on this compound evaluating each derivative for biofilm dispersion and β-lactam potentiation capabilities against M.?smegmatis. This study identified a compound that improved upon the biofilm dispersion capabilities of the lead compound. Interestingly, a different compound was identified with an increased ability to potentiate a subset of β-lactam antibiotics. These compounds indicate that biofilm dispersion and potentiation capabilities may not be associated.

INHIBITION OF BIOFILMS IN PLANTS WITH IMIDAZOLE DERIVATIVES

Disclosure is provided for methods of preventing, removing or inhibiting microbial biofilm formation or microbial infection in a plant or plant part thereof, including applying thereto a treatment effective amount of an active compound as described herein

Inhibition and dispersion of Pseudomonas aeruginosa biofilms with reverse amide 2-aminoimidazole oroidin analogues

The marine alkaloid oroidin along with a small library of reverse amide (RA) 2-aminoimidazoles were synthesized and assayed for anti-biofilm activity against PAO1 and PA14, two strains of the medically relevant γ-proteobacterium Pseudomonas aeruginosa. Analogues that contained a long, linear alkyl chain were more potent inhibitors than the natural product at preventing the formation of PAO1 and PA14 biofilms. The most active compound in the series was also shown to disperse established PAO1 and PA14 biofilms at low micromolar concentrations. The Royal Society of Chemistry.